Bystolic®: a β-blocker with benefits?
Metadata[+] Show full item record
Bystolic (nebivolol) has not demonstrated superiority to other β-blockers for lowering blood pressure (BP), but may be associated with fewer side effects. It has been evaluated only in studies assessing the intermediate outcome of BP lowering, not patient-oriented outcomes, such as cardiovascular morbidity or mortality. Because this drug is not available in a generic formulation, Bystolic's place in hypertension therapy must be evaluated considering price and postulated advantages.
Evidence Based Practice 11(12): 09-10.